 
A newly approved lung cancer drug shows promise in improving survival in patients whose tumors carry a common and tough-to-treat genetic mutation, researchers say. Sotorasib — brand name Lumakras — was approved May 28 by the U.S. Food and Drug Administration as a targeted therapy for non-small cell lung cancer patients with tumors that express… read on > read on >
 
 








 
 
 
 
 
 
 
 
 


-300x181.jpeg)








